Arcellx, Inc

Coherus BioSciences, Inc., based in Redwood City, CA, is dedicated to advancing innovative cancer therapeutics, focusing on next-generation combination therapies to improve treatment outcomes for patients living with hard-to-treat tumors. The company offers a diverse portfolio of immuno-oncology therapies, including the FDA-approved toripalimab-tpzi, aimed at enhancing survival rates for individuals with recurrent or metastatic nasopharyngeal carcinoma. With a strong emphasis on clinical trials and research, Coherus is committed to developing multiple investigational drug candidates that target the tumor microenvironment. Their strategic transformation to Coherus Oncology underlines their exclusive focus on pioneering solutions to combat cancer and support patients in their treatment journeys. Generated from the website

Aegis Life, Inc. is a biotechnology company based in San Carlos, CA, dedicated to preventing and treating infectious diseases. They utilize their proprietary nucleic acid delivery technology, Fusogenix PLV, to develop vaccines and therapeutics for existing and emerging contagions. With the ability to deliver genetic payloads directly into target cells, Fusogenix PLVs show great potential as a safe and effective nucleic acid delivery system. Aegis Life is committed to rapidly prototyping and bringing nucleic acid-based vaccines and therapies to the clinic. Through their optimized single-step microfluidic manufacturing process, Aegis Life is able to produce nucleic acid vaccines and therapeutics in a cost-effective and scalable manner. They are actively partnering with other institutions and companies to increase their GMP-manufacturing capacity, aiming to provide high volumes of vaccine and therapeutic doses to the public. With a pipeline that includes vaccine candidates against new and emerging viruses, underserved viruses, and viruses with complex antigenic requirements, Aegis Life is at the forefront of developing next-generation genetic vaccines and therapeutics to combat infectious diseases.Generated from the website

Vaxcyte, Inc., based in San Carlos, CA, is committed to eradicating bacterial infections like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella to safeguard every newborn and vulnerable adult worldwide. The company is at the forefront of innovation in vaccine development, particularly in addressing the persistent threat posed by Streptococcus pneumoniae bacteria, which continues to pose a significant health risk globally, especially for young children and the elderly. Vaxcyte leverages cutting-edge technology and unconventional approaches to create high-fidelity, broad-spectrum vaccines that can effectively combat bacteria's defenses while maintaining strong immunogenicity. Their pipeline includes potentially groundbreaking pneumococcal conjugate vaccines like VAX-31 and VAX-24, with ongoing research targeting other bacterial infections as well. Generated from the website content